Extracorporeal Blood Purification Can Cut Cardiac Surgery-Associated AKI
By Elana Gotkine HealthDay Reporter
FRIDAY, Oct. 11, 2024 -- For patients undergoing nonemergent cardiopulmonary bypass (CPB), use of an extracorporeal blood purification (EBP) device is associated with a lower rate of cardiac surgery-associated acute kidney injury (CSA-AKI), according to a study published online Oct. 9 in the Journal of the American Medical Association to coincide with the annual congress of the European Society of Intensive Care Medicine, held from Oct. 5 to 9 in Barcelona, Spain.
Xosé Pérez-Fernández, Ph.D., from L'Hospitalet de Llobregat in Barcelona, Spain, and colleagues conducted a double-blind, randomized clinical trial in two tertiary hospitals to examine whether use of an EBP device reduces CSA-AKI after CPB. Adults undergoing nonemergent cardiac surgery who were at high risk for CSA-AKI were randomly assigned to receive EBP or standard care (169 and 174 patients, respectively).
The researchers found that the rate of CSA-AKI was 28.4 and 39.7 percent in the EBP and standard-care groups, respectively. In most of the predefined clinical secondary end points or post hoc exploratory end points, there were no significant differences observed. In terms of CSA-AKI reduction, EBP was more effective for patients with chronic kidney disease, diabetes, hypertension, low left ventricular ejection fraction (<40 percent), and lower body mass index (<30 kg/m2) in a sensitivity analysis. The groups did not differ in adverse events.
"The use of a nonselective EBP device connected to the CPB circuit in a nonemergent population of patients undergoing cardiac surgery was associated with a significant reduction of CSA-AKI in the first seven days after the surgical procedure," the authors write.
One author disclosed ties to Exthera and SphingoTec.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-12 06:00
Read more
- Burden of Diabetes, Untreated Diabetes Increased From 1990 to 2022
- Brief Cognitive Behavioral Therapy Via Telehealth Cuts Suicide Attempts
- Trends in Obesity Treatment Show Surge in GLP-1 RAs, Drop in Surgeries
- Diadem Unveils Novel Findings on Early Alzheimer's Disease Detection Using p53-Specific Antibody at CTAD 2024
- Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with Keytruda (pembrolizumab) After Neoadjuvant Keytruda and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
- First Cases of Sexually Transmitted Ringworm Reported in the U.S.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions